Inventor · disambiguated record
Robert Schlegl
Also filed as: SCHLEGL ROBERT
27 granted patents·10 pending applications·135 citations·filing 2002–2024
96Inventor score
Files withVALNEVA AUSTRIA GMBH23VALNEVA SE7SCHLEGL ROBERT2BOEHRINGER INGELHEIM AUSTRIA1BOEHRINGER INGELHEIM RCV GMBH1
Top patents by PatentIndex Score
37 records- 0196US11219681B2Zika virus vaccineVALNEVA AUSTRIA GMBH·Filed 2020·Granted Jan 11, 2022·9 cites·26 claims
- 0296US10537630B2Virus purificationVALNEVA SE·Filed 2016·Granted Jan 21, 2020·15 cites·12 claims
- 0395US10744194B2Zika virus purificationVALNEVA AUSTRIA GMBH·Filed 2016·Granted Aug 18, 2020·11 cites·20 claims
- 0495US10660950B2Virus purificationVALNEVA SE·Filed 2016·Granted May 26, 2020·8 cites·14 claims
- 0595US10639365B2Zika virus vaccineVALNEVA AUSTRIA GMBH·Filed 2016·Granted May 5, 2020·6 cites·20 claims
- 0693US11684669B2CpG-adjuvanted SARS-CoV-2 virus vaccineVALNEVA AUSTRIA GMBH·Filed 2021·Granted Jun 27, 2023·6 cites·30 claims
- 0791US12011477B2Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus CHIKV-delta5NSP3VALNEVA SE·Filed 2022·Granted Jun 18, 2024·1 cites·22 claims
- 0891US11466058B2Mutant fragments of OspA and methods and uses relating theretoVALNEVA AUSTRIA GMBH·Filed 2019·Granted Oct 11, 2022·4 cites·10 claims
- 0991US11331382B2Zika virus purificationVALNEVA AUSTRIA GMBH·Filed 2016·Granted May 17, 2022·4 cites·9 claims
- 1091US10544194B2Mutant fragments of OspA and methods and uses relating theretoVALNEVA AUSTRIA GMBH·Filed 2016·Granted Jan 28, 2020·8 cites·9 claims
- 1191US7651848B2Method for refolding a proteinBOEHRINGER INGELHEIM RCV GMBH·Filed 2007·Granted Jan 26, 2010·18 cites·15 claims
- 1291US2025018023A1Zika Virus VaccineVALNEVA AUSTRIA GMBH·Filed 2024·Application pending·0 cites
- 1389US10668146B2Methods for preparing aluminum precipitate compounds for use in therapeutics and vaccinesVALNEVA AUSTRIA GMBH·Filed 2017·Granted Jun 2, 2020·3 cites·12 claims
- 1488US12102673B2Zika virus vaccineVALNEVA AUSTRIA GMBH·Filed 2023·Granted Oct 1, 2024·0 cites·32 claims
- 1587US11951163B2Zika virus vaccineVALNEVA AUSTRIA GMBH·Filed 2023·Granted Apr 9, 2024·0 cites·58 claims
- 1687US11484587B2Method of producing pharmaceutical compositions comprising immunogenic Chikungunya virus CHIKV-Delta5nsP3VALNEVA SE·Filed 2018·Granted Nov 1, 2022·3 cites·19 claims
- 1787US8765148B21C31 nanoparticlesWIZEL BENJAMIN·Filed 2011·Granted Jul 1, 2014·26 cites·10 claims
- 1884US12214033B2Virus purificationVALNEVA SE·Filed 2022·Granted Feb 4, 2025·0 cites·14 claims
- 1983US11110170B2Aluminum compounds for use in therapeutics and vaccinesVALNEVA AUSTRIA GMBH·Filed 2020·Granted Sep 7, 2021·1 cites·20 claims
- 2083US10662412B2Aseptic purification process for virusesVALNEVA SE·Filed 2016·Granted May 26, 2020·2 cites·17 claims
- 2182US2023295245A1Mutant fragments of ospa and methods and uses relating theretoVALNEVA AUSTRIA GMBH·Filed 2022·Application pending·0 cites
- 2281US12005111B2Zika virus vaccineVALNEVA AUSTRIA GMBH·Filed 2021·Granted Jun 11, 2024·0 cites·58 claims
- 2380US9913898B2Aluminum compounds for use in therapeutics and vaccinesVALNEVA AUSTRIA GMBH·Filed 2016·Granted Mar 13, 2018·2 cites·18 claims
- 2480US9884115B2Aluminum compounds for use in therapeutics and vaccinesVALNEVA AUSTRIA GMBH·Filed 2015·Granted Feb 6, 2018·2 cites·14 claims
- 2574US9895437B2Aluminum compounds for use in therapeutics and vaccinesSCHLEGL ROBERT·Filed 2012·Granted Feb 20, 2018·2 cites·18 claims
- 2665US7060460B2Method for reconstituting a recombinant protein to its biologically active formBOEHRINGER INGELHEIM AUSTRIA·Filed 2002·Granted Jun 13, 2006·4 cites·33 claims
- 2763US11629339B2Aseptic purification process for virusesVALNEVA SE·Filed 2020·Granted Apr 18, 2023·0 cites·12 claims
- 2863US2024026412A1Improved methods of producing a lipidated proteinVALNEVA AUSTRIA GMBH·Filed 2021·Application pending·0 cites
- 2963US2023398210A1Improvements in vaccine formulations for medical useVALNEVA AUSTRIA GMBH·Filed 2021·Application pending·0 cites
- 3062US2015232517A1MUTANT FRAGMENTS OF OspA AND METHODS AND USES RELATING THERETOVALNEVA AUSTRIA GMBH·Filed 2013·Application pending·0 cites
- 3162US2022298493A1Inactivation process for virusesVALNEVA AUSTRIA GMBH·Filed 2022·Application pending·0 cites
- 3254US9359412B2OprF/I fusion proteins, their preparation and useSCHLEGL ROBERT·Filed 2012·Granted Jun 7, 2016·0 cites·12 claims
- 3354US2024293531A1Inactivated sars-cov-2 virus vaccineVALNEVA AUSTRIA GMBH·Filed 2021·Application pending·0 cites
- 3454US2023092650A1Coronavirus vaccines comprising a tlr9 agonistDYNAVAX TECH CORP·Filed 2021·Application pending·0 cites
- 3551US9248180B2IC31 nanoparticlesVALNEVA AUSTRIA GMBH·Filed 2014·Granted Feb 2, 2016·0 cites·17 claims
- 3649US2016362480A1Novel oprf/i fusion proteins, their preparation and useVALNEVA AUSTRIA GMBH·Filed 2016·Application pending·0 cites
- 3741US2013266575A1OprF/I AGENTS AND USE THEREOF IN HOSPITALIZED AND OTHER PATIENTSINTERCELL AG·Filed 2013·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Robert Schlegl files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →